Genetics of Parkinson's Disease—An Overview

Blue Books of Neurology

Volumn 34, Issue C, 2010, Pages 15-39

  Klein, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84963746660     PISSN: 1877184X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-1-4160-6641-5.00002-7     Document Type: Chapter

References (166)

1. Thomas, B., Beal, M.F., Parkinson's disease. Hum Mol Genet 16:Spec No. 2 (2007), R183–R194.
2. Galpern, W.R., Lang, A.E., Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59 (2006), 449–458.
3. Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988), 745–752.
4. Sveinbjornsdottir, S., Hicks, A.A., Jonsson, T., et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 343 (2000), 1765–1770.
5. Lesage, S., Durr, A., Tazir, M., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354 (2006), 422–423.
6. Ozelius, L.J., Senthil, G., Saunders-Pullman, R., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354 (2006), 424–425.
7. Klein, C., Lohmann-Hedrich, K., Rogaeva, E., et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6 (2007), 652–662.
8. Polymeropoulos, M.H., Lavedan, C., Leroy, E., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
9. Singleton, A.B., Farrer, M., Johnson, J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 2003, 841.
10. Singleton, A., Gwinn-Hardy, K., Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet 364 (2004), 1105–1107.
11. Nishioka, K., Hayashi, S., Farrer, M.J., et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59 (2006), 298–309.
12. Fuchs, J., Nilsson, C., Kachergus, J., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68 (2007), 916–922.
13. Farrer, M.J., Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7 (2006), 306–318.
14. Ahn, T.B., Kim, S.Y., Kim, J.Y., et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 1:70(1) (2008), 43–49 E7.
15. Troiano, A.R., Cazeneuve, C., Le Ber, I., et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology, 71(16), 2008, 1295.
16. Brueggemann N, Per O, Grünewald A, et al: Alpha-synuclein gene duplication is present sporadic Parkinson disease. Neurology.
17. Berg, D., Niwar, M., Maass, S., et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord 20 (2005), 1191–1194.
18. Maraganore, D.M., de Andrade, M., Elbaz, A., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296 (2006), 661–670.
19. Vekrellis, K., Rideout, H.J., Stefanis, L., Neurobiology of alpha-synuclein. Mol Neurobiol 30 (2004), 1–22.
20. Kontopoulos, E., Parvin, J.D., Feany, M.B., Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15 (2006), 3012–3023.
21. Anderson, J.P., Walker, D.E., Goldstein, J.M., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281 (2006), 29739–29752.
22. Spillantini, M.G., Schmidt, M.L., Lee, V.M., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
23. Leroy, E., Boyer, R., Auburger, G., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998), 451–452.
24. Liu, Y., Fallon, L., Lashuel, H.A., et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002), 209–218.
25. Zimprich, A., Biskup, S., Leitner, P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.
26. Paisan-Ruiz, C., Jain, S., Evans, E.W., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004), 595–600.
27. Kay, D.M., Zabetian, C.P., Factor, S.A., et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 21 (2006), 519–523.
28. Goldwurm, S., Di Fonzo, A., Simons, E.J., et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet, 42, 2005, e65.
29. Hedrich, K., Winkler, S., Hagenah, J., et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 21 (2006), 1506–1510.
30. Funayama, M., Hasegawa, K., Ohta, E., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 (2005), 918–921.
31. Zabetian, C.P., Samii, A., Mosley, A.D., et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005), 741–744.
32. Farrer, M., Stone, J., Mata, I.F., et al. LRRK2 mutations in Parkinson disease. Neurology 65 (2005), 738–740.
33. Paisan-Ruiz, C., Lang, A.E., Kawarai, T., et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65 (2005), 696–700.
34. Mata, I.F., Kachergus, J.M., Taylor, J.P., et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6 (2005), 171–177.
35. Kachergus, J., Mata, I.F., Hulihan, M., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76 (2005), 672–680.
36. Lesage, S., Ibanez, P., Lohmann, E., et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 58 (2005), 784–787.
37. Berg, D., Schweitzer, K., Leitner, P., et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128 (2005), 3000–3011.
38. Di Fonzo, A., Tassorelli, C., De Mari, M., et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14 (2006), 322–331.
39. Orr-Urtreger, A., Shifrin, C., Rozovski, U., et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?. Neurology 69 (2007), 1595–1602.
40. Kay, D.M., Kramer, P., Higgins, D., et al. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord 20 (2005), 1077–1078.
41. Ishihara, L., Warren, L., Gibson, R., et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63 (2006), 1250–1254.
42. Wszolek, Z.K., Pfeiffer, R.F., Tsubol, Y., et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology, 62(9), 2004;.
43. Gloeckner, C.J., Kinkl, N., Schumacher, A., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15 (2006), 223–232.
44. Smith, W.W., Pei, Z., Jiang, H., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9 (2006), 1231–1233.
45. West, A.B., Moore, D.J., Biskup, S., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102 (2005), 16842–16847.
46. Smith, W.W., Pei, Z., Jiang, H., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102 (2005), 18676–18681.
47. Greggio, E., Jain, S., Kingsbury, A., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23 (2006), 329–341.
48. Mata, I.F., Wedemeyer, W.J., Farrer, M.J., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29 (2006), 286–293.
49. Galter, D., Westerlund, M., Carmine, A., et al. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59 (2006), 714–719.
50. Martins, L.M., Morrison, A., Klupsch, K., et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 24 (2004), 9848–9862.
51. Strauss, K.M., Martins, L.M., Plun-Favreau, H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14 (2005), 2099–2111.
52. Plun-Favreau, H., Klupsch, K., Moisoi, N., et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9 (2007), 1243–1252.
53. Lohmann, E., Periquet, M., Bonifati, V., et al. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 54 (2003), 176–185.
54. Pramstaller, P.P., Schlossmacher, M.G., Jacques, T.S., et al. Lewy body Parkinson's disease in a large pedigree with. 77 Parkin mutation carriers. Ann Neurol 58 (2005), 411–422.
55. Kitada, T., Asakawa, S., Hattori, N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998), 605–608.
56. Hedrich, K., Eskelson, C., Wilmot, B., et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 19 (2004), 1146–1157.
57. Hedrich, K., Kann, M., Lanthaler, A.J., et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10 (2001), 1649–1656.
58. Shimura, H., Hattori, N., Kubo, S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000), 302–305.
59. Sriram, S.R., Li, X., Ko, H.S., et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 14 (2005), 2571–2586.
60. Matsuda, N., Kitami, T., Suzuki, T., et al. Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281 (2006), 3204–3209.
61. Hampe, C., Ardila-Osorio, H., Fournier, M., et al. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15 (2006), 2059–2075.
62. Shimura, H., Schlossmacher, M.G., Hattori, N., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001), 263–269.
63. Schlossmacher, M.G., Frosch, M.P., Gai, W.P., et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160 (2002), 1655–1667.
64. Feany, M.B., Pallanck, L.J., Parkin: a multipurpose neuroprotective agent?. Neuron 38 (2003), 13–16.
65. Greene, J.C., Whitworth, A.J., Kuo, I., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 100 (2003), 4078–4083.
66. Palacino, J.J., Sagi, D., Goldberg, M.S., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004), 18614–18622.
67. Rosen, K.M., Veereshwarayya, V., Moussa, C.E., et al. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem 281 (2006), 12809–12816.
68. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004), 1158–1160.
69. Healy, D.G., Abou-Sleiman, P.M., Gibson, J.M., et al. PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63 (2004), 1486–1488.
70. Rogaeva, E., Johnson, J., Lang, A.E., et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 61 (2004), 1898–1904.
71. Li, Y., Tomiyama, H., Sato, K., et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology 64 (2005), 1955–1957.
72. Klein, C., Djarmati, A., Hedrich, K., et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 13 (2005), 1086–1093.
73. Bonifati, V., Rohe, C.F., Breedveld, G.J., et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65 (2005), 87–95.
74. Tan, E.K., Yew, K., Chua, E., et al. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21 (2006), 789–793.
75. Gandhi, S., Muqit, M.M., Stanyer, L., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006), 1720–1731.
76. Silvestri, L., Caputo, V., Bellacchio, E., et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14 (2005), 3477–3492.
77. Petit, A., Kawarai, T., Paitel, E., et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280 (2005), 34025–34032.
78. Beilina, A., Van Der Brug, M., Ahmad, R., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 102 (2005), 5703–5708.
79. Sim, C.H., Lio, D.S., Mok, S.S., et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15 (2006), 3251–3262.
80. Muqit, M.M., Abou-Sleiman, P.M., Saurin, A.T., et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem 98 (2006), 156–169.
81. Greenamyre, J.T., Hastings, T.G., Biomedicine: Parkinson's—divergent causes, convergent mechanisms. Science 304 (2004), 1120–1122.
82. Clark, I.E., Dodson, M.W., Jiang, C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006), 1162–1166.
83. Park, J., Lee, S.B., Lee, S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006), 1157–1161.
84. Yang, Y., Gehrke, S., Imai, Y., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 103 (2006), 10793–10798.
85. Exner, N., Treske, B., Paquet, D., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27 (2007), 12413–12418.
86. Pridgeon, J.W., Olzmann, J.A., Chin, L.S., Li, L., PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol, 5, 2007, e172.
87. Weihofen, A., Ostaszewski, B., Minami, Y., Selkoe, D.J., Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet 17 (2007), 602–616.
88. Kitada, T., Pisani, A., Porter, D.R., et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104 (2007), 11441–11446.
89. Cookson, M.R., Dauer, W., Dawson, T., et al. The roles of kinases in familial Parkinson's disease. J Neurosci 27 (2007), 11865–11868.
90. Bonifati, V., Rizzu, P., van Baren, M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003), 256–259.
91. Hedrich, K., Djarmati, A., Schafer, N., et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62 (2004), 389–394.
92. Goldberg, M.S., Pisani, A., Haburcak, M., et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 (2005), 489–496.
93. Canet-Aviles, R.M., Wilson, M.A., Miller, D.W., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101 (2004), 9103–9108.
94. Kim, R.H., Smith, P.D., Aleyasin, H., et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 102 (2005), 5215–5220.
95. Meulener, M.C., Xu, K., Thomson, L., et al. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci U S A 103 (2006), 12517–12522.
96. Andres-Mateos, E., Perier, C., Zhang, L., et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 104 (2007), 14807–14812.
97. Ramirez, A., Heimbach, A., Grundemann, J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 (2006), 1184–1191.
98. Williams, D.R., Hadeed, A., al-Din, A.S., et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 20 (2005), 1264–1271.
99. Di Fonzo, A., Chien, H.F., Socal, M., et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68 (2007), 1557–1562.
100. Massey, A.C., Zhang, C., Cuervo, A.M., Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol 73 (2006), 205–235.
101. Rubinsztein, D.C., The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443 (2006), 780–786.
102. Tang, B., Xiong, H., Sun, P., et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 (2006), 1816–1825.
103. Dachsel, J.C., Mata, I.F., Ross, O.A., et al. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett 410 (2006), 80–84.
104. Ferreira, J.J., Guedes, L.C., Rosa, M.M., et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord 22 (2007), 1194–1201.
105. Le, W.D., Xu, P., Jankovic, J., et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33 (2003), 85–89.
106. Grimes, D.A., Han, F., Panisset, M., et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord 21 (2006), 906–909.
107. Wellenbrock, C., Hedrich, K., Schafer, N., et al. NR4A2 mutations are rare among European patients with familial Parkinson's disease. Ann Neurol, 54, 2003, 415.
108. Zimprich, A., Asmus, F., Leitner, P., et al. Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 4 (2003), 219–220.
109. Hering, R., Petrovic, S., Mietz, E.M., et al. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 62 (2004), 1231–1232.
110. Engelender, S., Kaminsky, Z., Guo, X., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22 (1999), 110–114.
111. Chung, K.K., Zhang, Y., Lim, K.L., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7 (2001), 1144–1150.
112. Marx, F.P., Holzmann, C., Strauss, K.M., et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 12 (2003), 1223–1231.
113. Aharon-Peretz, J., Rosenbaum, H., Gershoni-Baruch, R., Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351 (2004), 1972–1977.
114. Goker-Alpan, O., Giasson, B.I., Eblan, M.J., et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67 (2006), 908–910.
115. Goker-Alpan, O., Schiffmann, R., LaMarca, M.E., et al. Parkinsonism among Gaucher disease carriers. J Med Genet 41 (2004), 937–940.
116. Eblan, M.J., Scholz, S., Stubblefield, B., et al. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neurosci Lett 404 (2006), 163–165.
117. Sato, C., Morgan, A., Lang, A.E., et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 20 (2005), 367–370.
118. Ziegler, S.G., Eblan, M.J., Gutti, U., et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91 (2007), 195–200.
119. Toft, M., Pielsticker, L., Ross, O.A., et al. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66 (2006), 415–417.
120. Mancuso, M., Filosto, M., Bellan, M., et al. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology 62 (2004), 316–318.
121. Luoma, P., Melberg, A., Rinne, J.O., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364 (2004), 875–882.
122. Davidzon, G., Greene, P., Mancuso, M., et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 59 (2006), 859–862.
123. Thyagarajan, D., Bressman, S., Bruno, C., et al. A novel mitochondrial. 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol 48 (2000), 730–736.
124. Grasbon-Frodl, E.M., Kosel, S., Sprinzl, M., et al. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease. Neurogenetics 2 (1999), 121–127.
125. Nolte, D., Niemann, S., Muller, U., Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A 100 (2003), 10347–10352.
126. Makino, S., Kaji, R., Ando, S., et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 80 (2007), 393–406.
127. Muller, U., Herzfeld, T., Nolte, D., The TAF1/DYT3 multiple transcript system in X-linked dystonia-parkinsonism. Am J Hum Genet 81 (2007), 415–417.
128. Lee, L.V., Pascasio, F.M., Fuentes, F.D., Viterbo, G.H., Torsion dystonia in Panay, Philippines. Adv Neurol 14 (1976), 137–151.
129. Nar, H., Huber, R., Auerbach, G., et al. Active site topology and reaction mechanism of GTP cyclohydrolase I. Proc Natl Acad Sci U S A 92 (1995), 12120–12125.
130. Segawa, M., Hosaka, A., Miyagawa, F., et al. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 14 (1976), 215–233.
131. Grimes, D.A., Barclay, C.L., Duff, J., et al. Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. J Neurol Neurosurg Psychiatry 72 (2002), 801–804.
132. de Carvalho Aguiar, P., Aguiar, P., Sweadner, K., et al. Mutations in the Na+/K+-ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 43 (2004), 169–175.
133. Brashear, A., Dobyns, W.B., de Carvalho Aguiar, P., et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 130 (2007), 828–835.
134. Lee, J.Y., Gollamudi, S., Ozelius, L.J., et al. ATP1A3 mutation in the first Asian case of rapid-onset dystonia-parkinsonism. Mov Disord 22 (2007), 1808–1809.
135. Schols, L., Peters, S., Szymanski, S., et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 57 (2000), 1495–1500.
136. Schols, L., Kruger, R., Amoiridis, G., et al. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 64 (1998), 67–73.
137. Abou-Sleiman, P.M., Muqit, M.M., McDonald, N.Q., et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 60 (2006), 414–419.
138. Criscuolo, C., Volpe, G., De Rosa, A., et al. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord 21 (2006), 1265–1267.
139. Toft, M., Myhre, R., Pielsticker, L., et al. PINK1 mutation heterozygosity and the risk of Parkinson's disease. J Neurol Neurosurg Psychiatry 78 (2007), 82–84.
140. Djarmati, A., Hedrich, K., Svetel, M., et al. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease?. Mov Disord 21 (2006), 1526–1530.
141. Hedrich, K., Hagenah, J., Djarmati, A., et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch Neurol 63 (2006), 833–838.
142. Lincoln, S.J., Maraganore, D.M., Lesnick, T.G., et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord 18 (2003), 1306–1311.
143. Kay, D.M., Moran, D., Moses, L., et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 61 (2007), 47–54.
144. Clark, L.N., Afridi, S., Karlins, E., et al. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol 63 (2006), 548–552.
145. Hedrich, K., Marder, K., Harris, J., et al. Evaluation of. 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 58 (2002), 1239–1246.
146. Sun, M., Latourelle, J.C., Wooten, G.F., et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 63 (2006), 826–832.
147. Tan, E.K., Zhao, Y., Skipper, L., et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120 (2006), 857–863.
148. Healy, D.G., Abou-Sleiman, P.M., Casas, J.P., et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol 59 (2006), 627–633.
149. Mizuta, I., Satake, W., Nakabayashi, Y., et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 15 (2006), 1151–1158.
150. Maraganore, D.M., de Andrade, M., Lesnick, T.G., et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77 (2005), 685–693.
151. Elbaz, A., Nelson, L.M., Payami, H., et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol 5 (2006), 917–923.
152. Farrer, M.J., Haugarvoll, K., Ross, O.A., et al. Genomewide association, Parkinson disease, and PARK10. Am J Hum Genet 78 (2006), 1084–1088.
153. Bialecka, M., Kurzawski, M., Klodowska-Duda, G., et al. Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease risk. Neurosci Lett 399 (2006), 121–123.
154. Clarimon, J., Scholz, S., Fung, H.C., et al. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet 78 (2006), 1082–1084.
155. Fung, H.C., Scholz, S., Matarin, M., et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5 (2006), 911–916.
156. Papapetropoulos, S., Ffrench-Mullen, J., McCorquodale, D., et al. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Expr 13 (2006), 205–215.
157. Jin, J., Hulette, C., Wang, Y., et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 5 (2006), 1193–1204.
158. Klein, C., Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63 (2006), 328–334.
159. Klein, C., Schlossmacher, M., The genetics of Parkinson disease. Nat Clin Pract Neurol 2 (2006), 136–146.
160. McInerney-Leo, A., Hadley, D.W., Gwinn-Hardy, K., Hardy, J., Genetic testing in Parkinson's disease. Mov Disord 20 (2005), 1–10.
161. Djarmati, A., Guzvic, M., Grunewald, A., et al. Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. Mov Disord 22 (2007), 1708–1714.
162. Clark, L.N., Haamer, E., Mejia-Santana, H., et al. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord 22 (2007), 932–937.
163. Chan, C.S., Guzman, J.N., Ilijic, E., et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature 447 (2007), 1081–1086.
164. Sulzer, D., Schmitz, Y., Parkinson's disease: return of an old prime suspect. Neuron 55 (2007), 8–10.
165. Hebert, S.S., De Strooper, B., Molecular biology: miRNAs in neurodegeneration. Science 317 (2007), 1179–1180.
166. Takahashi, K., Tanabe, K., Ohnuki, M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.